Share on LinkedInShare on LinkedIn

ARTICLE · 27 FEBRUARY 2025

Patenting AI/ML Life Sciences And TechBio Innovations – How Much Disclosure Is Sufficient?

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Contributor
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Mintz is a litigation powerhouse and business accelerator serving leaders in life sciences, private...

View firm profile
Explore more from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

In recent years, the rapid advancement of artificial intelligence (AI) and machine learning (ML) technologies has sparked a wave of innovation across various sectors, particularly in life sciences.

United StatesIntellectual Property

In recent years, the rapid advancement of artificial intelligence (AI) and machine learning (ML) technologies has sparked a wave of innovation across various sectors, particularly in life sciences. ML technologies have increasingly been incorporated into medical devices, leading to the U.S. Food and Drug Administration (FDA) approval of approximately 950 AI-enabled medical devices.1 Machine learning is also being used today in drug discovery, patient care, preclinical and clinical testing, as well as drug validation studies. However, as the patent landscape for these technologies expands, a critical issue has come to the forefront: the sufficiency of disclosure in AI/ML patents: How much detail is enough to meet legal standards and foster innovation while protecting intellectual property?

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from